Biogen has announced that it has initiated a phase 3 study of investigational felzartamab in adults with primary membranous ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Biogen Inc. stands sixth on our list among the most ...

Investing.com - Truist Securities hat die Beobachtung der Biogen-Aktie (NASDAQ: BIIB) am Montag mit einer "Halten"-Einstufung und einem Kursziel von 142,00 $ aufgenommen. Laut Daten von InvestingPro w ...

Biogen (($CC:HTER)) announced an update on their ongoing clinical study. Biogen Inc. (BIIB) has announced an update on its ...

Biogen beschäftigt in North Carolina über 1.500 Mitarbeiter in der Produktion und Technik sowie mehr als 400 qualifizierte ...

Biogen, one of the world's largest biotechnology companies, plans to invest $2 billion and build a new manufacturing facility ...

Additionally, Biogen has initiated a Phase 3 trial of felzartamab for primary membranous nephropathy (PMN), a rare kidney disease, with results expected in 2029. This marks the company’s third Phase 3 ...

Vera Therapeutics' Phase 3 data on atacicept sparks optimism for IgAN treatment, but competition and market challenges may ...

In a report released today, Evan Seigerman from BMO Capital maintained a Hold rating on Biogen, with a price target of $128.00. The company’s shares closed yesterday at $134.46.

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen, with a price target of $208.00. The company’s shares closed yesterday at $133.02.